Auto-injector with anti-roll features

Patent metadata

Field	Value
Publication number	US-11484654-B2
Application number	US-201816626669-A
Country	US
Kind code	B2
Filing date	Jun 29, 2018
Priority date	Jun 30, 2017
Publication date	Nov 1, 2022
Grant date	Nov 1, 2022

Abstract

The present disclosure relates to a therapeutic agent delivery device with anti-roll features. In one embodiment, a therapeutic agent delivery device may include a tubular body including a first end portion, a second end portion, and a lumen extending between the first end portion and the second portion. An outer surface of the tubular body includes a first opening in communication with the lumen. The outer surface of the tubular body further may include a ledge extending around a periphery of the first opening, and a portion of the ledge closest to the second end portion of the tubular body may be shaped as an arrowhead. The therapeutic agent delivery device also may include a cap configured to engage the second end portion of the tubular body, which may include a curved sidewall extending radially outward. The curved sidewall may include a protrusion.

First claim

What is claimed is:

1. A therapeutic agent delivery device, comprising:
a tubular body including a first end portion, a second end portion, and a lumen extending between the first end portion and the second end portion, wherein an outer surface of the tubular body includes a first opening in communication with the lumen, wherein the first opening is surrounded by a first opening periphery, and wherein the first opening periphery includes a generally circular or oval shape, and the outer surface of the tubular body further includes a ledge extending around the first opening periphery, the ledge extending away from the opening by a first width, wherein a portion of the ledge closest to the second end portion of the tubular body is shaped as an arrowhead having an apex, and wherein a second width of the ledge at the apex is larger than the first width; and
a cap configured to engage the second end portion of the tubular body, wherein the cap includes a central longitudinal axis, a first end having a first cross-sectional dimension, and a second end having a second cross-sectional dimension larger than the first cross-sectional dimension, and wherein the cap further includes a sidewall extending radially outward from the first end to the second end, and wherein the sidewall includes a protrusion.

2. The therapeutic agent delivery device of claim 1 , wherein the therapeutic agent delivery device is an auto-injector.

3. The therapeutic agent delivery device of claim 1 , wherein the lumen is configured to receive a syringe therein.

4. The therapeutic agent delivery device of claim 3 , wherein the syringe includes a volume of the therapeutic agent, and wherein the first opening is configured to permit visualization of the volume of the therapeutic agent.

5. The therapeutic agent delivery device of claim 1 , wherein, when the cap is not engaged with the tubular body, the ledge is configured to restrict rolling of the tubular body.

6. The therapeutic agent delivery device of claim 1 , wherein, when the cap is engaged with the tubular body, only the protrusion is configured to restrict rolling of the therapeutic agent delivery device.

7. The therapeutic agent delivery device of claim 1 , wherein the protrusion includes a plurality of protrusions.

8. The therapeutic agent delivery device of claim 7 , wherein each protrusion of the plurality of protrusions is circumferentially spaced from an adjacent protrusion.

9. The therapeutic agent delivery device of claim 7 , further comprising a recess disposed between adjacent protrusions.

10. The therapeutic agent delivery device of claim 1 , wherein the protrusion includes a first end and a second end, wherein the first end of the protrusion is spaced from the central longitudinal axis of the cap by a first distance, and wherein the second end of the protrusion is spaced from the central longitudinal axis of the cap by a second distance greater than the first distance.

11. The therapeutic agent delivery device of claim 1 , wherein the outer surface of the tubular body further includes a second opening disposed diametrically opposite to the first opening.

12. The therapeutic agent delivery device of claim 1 , wherein the therapeutic agent delivery device contains dupilumab.

13. The therapeutic agent delivery device of claim 1 , wherein a portion of the ledge has a generally hastate configuration.

14. The therapeutic agent delivery device of claim 1 , wherein the cap includes a recess having an arrowhead-like shape.

Assignees

• Regeneron Pharma

Inventors

• Nicholas Courtney
• Barton Scott
• Burgess Bart E
• Goraltchouk Alexei

Classifications

• A61M5/3129 Primary

  Syringe barrels (A61M5/3205 and A61M5/50 take precedence) · CPC title

• A61M5/178

  Syringes · CPC title

• A61M5/20 Primary

  Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically (A61M5/142 {, A61M5/46} take precedence; {hypodermic projectiles F42B12/54}) · CPC title

• A61M5/3202 Primary

  Devices for protection of the needle before use, e.g. caps (A61M5/50 takes precedence; for infusion spikes A61M5/1626; protectors for sharps A61B50/3001) · CPC title

• A61M5/31 Primary

  Details · CPC title